company background image
SCYX logo

SCYNEXIS NasdaqGM:SCYX Stock Report

Last Price

US$1.07

Market Cap

US$40.6m

7D

0%

1Y

-50.0%

Updated

02 Feb, 2025

Data

Company Financials +

SCYNEXIS, Inc.

NasdaqGM:SCYX Stock Report

Market Cap: US$40.6m

SCYX Stock Overview

A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. More details

SCYX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 27.55% per year

Analysts in good agreement that stock price will rise by 523.1%

Risk Analysis

Does not have a meaningful market cap ($41M)


My Notes

Capture your thoughts, links and company narrative

SCYNEXIS, Inc. Competitors

Opus Genetics

NasdaqCM:IRD

US$35.0m

Provectus Biopharmaceuticals

OTCPK:PVCT

US$46.3m

IGC Pharma

NYSEAM:IGC

US$24.8m

Pulmatrix

NasdaqCM:PULM

US$28.1m

Price History & Performance

Summary of share price highs, lows and changes for SCYNEXIS
Historical stock prices
Current Share PriceUS$1.07
52 Week HighUS$3.07
52 Week LowUS$0.90
Beta1.53
1 Month Change-24.11%
3 Month Change-18.94%
1 Year Change-50.00%
3 Year Change-76.74%
5 Year Change-87.26%
Change since IPO-98.81%

Recent News & Updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Shareholder Returns

SCYXUS PharmaceuticalsUS Market
7D0%2.4%-0.8%
1Y-50.0%4.3%22.7%

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: SCYX underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement10.3%
Pharmaceuticals Industry Average Movement10.3%
Market Average Movement6.4%
10% most volatile stocks in US Market18.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: SCYX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: SCYX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199929David Angulowww.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
SCYX fundamental statistics
Market capUS$40.61m
Earnings (TTM)-US$36.44m
Revenue (TTM)US$8.57m

4.7x

P/S Ratio

-1.1x

P/E Ratio

Is SCYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCYX income statement (TTM)
RevenueUS$8.57m
Cost of RevenueUS$14.68m
Gross Profit-US$6.12m
Other ExpensesUS$30.32m
Earnings-US$36.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin-71.42%
Net Profit Margin-425.41%
Debt/Equity Ratio22.6%

How did SCYX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 06:02
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SCYNEXIS, Inc. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jonathan AschoffB. Riley Wealth
Brian Kemp DolliverBrookline Capital Markets